Palobiofarma has started the recruitment of a Phase I clinical trial evaluating the safety and tolerability of the novel PDE10/A2a dual antagonist PBF-999 in patients with solid tumors. The trial will be conducted at the Vall D Hebron Hospital, in Barcelona, Spain.
News
Palobiofarma initiates clinical development of it´s novel dual PDE10/A2a antagonist in solid tumors
2
Related News
2
Palobiofarma advances it´s broad clinical pipeline
Palobiofarma has started the recruitment of a Phase I clinical trial evaluating the safety and...
No Comments
2
Palobiofarma achieves “first patient first visit” in two key Phase II studies
Palobiofarma has started the recruitment of a Phase I clinical trial evaluating the safety and...
No Comments
0
Palobiofarma has started the clinical development of PBF-1650
Palobiofarma has started the recruitment of a Phase I clinical trial evaluating the safety and...
No Comments
2
Palobiofarma completed the dose escalation part of the Phase I study with PBF-999 in cancer patients
Palobiofarma has started the recruitment of a Phase I clinical trial evaluating the safety and...
3 Comments
2
FDA grants Palobiofarma approval to start second anti-cancer study in USA
Palobiofarma has started the recruitment of a Phase I clinical trial evaluating the safety and...
No Comments